{"analyses":[{"ciLowerLimit":"1.20","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.77","groupDescription":"Hazard Ratio and Confidence Interval were based on analyses on all randomized subjects","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Hazard Ratio (HR)","paramValue":"1.46","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.0","upperLimit":"3.1","value":"3.1"},{"groupId":"OG001","lowerLimit":"5.6","upperLimit":"6.0","value":"5.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"215"},{"groupId":"OG001","value":"204"}],"units":"Participants"}],"description":"The time to cCCyR for all randomized participants is defined as the time from the randomization date until criteria are first met for complete cytogenic response (provided it is confirmed later). The time to cCCyR analysis censors nonresponders who do not progress at their last cytogenetic assessments and nonresponders who progress at the maximum time of all randomized participants.\n\n.","dispersionType":"95% Confidence Interval","groups":[{"description":"Tablets, oral, dasatinib 100 mg once daily (QD)","id":"OG000","title":"Dasatinib"},{"description":"Tablets, oral, imatinib 400 mg once daily (QD)","id":"OG001","title":"Imatinib"}],"paramType":"MEDIAN","populationDescription":"All randomized participants who achieved cCCyR","reportingStatus":"POSTED","timeFrame":"Day 1 to 5 years","title":"Time to Confirmed Complete Cytogenic Response (cCCyR) Overall","type":"SECONDARY","unitOfMeasure":"Months"}